Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 8 October 2025 - 17 October 2025

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

LLY Stock Skyrockets, Then Dips on Pricing Jitters Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospectsts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchisests2.tech. For example,
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levelsreuters.comreuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B)reuters.comreuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has intensified: U.S. rival Eli
17 October 2025
···
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

PRAX Stock Soars on Historic Trial Win Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion
17 October 2025
····
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX Stock Climbs on Arbli Launch Pills and a daily pill organizer: Arbli’s liquid formulation helps patients (especially children/elderly) who can’t swallow tablets. Scienture’s stock jumped sharply on Oct. 16 after the company formally launched Arbli™ in the U.S. market. In a GlobeNewswire press release that morning, Scienture announced that Arbli™ is now shipping through major pharmaceutical wholesalers nationwideglobenewswire.com. Arbli is the first FDA-approved oral liquid form of losartan, a top-selling blood pressure drug. The launch news and accompanying marketing caused traders to bid up SCNX: one trader wrote that shares moved “from yesterday’s close around 72 cents to nearly
16 October 2025
····
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Stock Price Rollercoaster in 2025 Adaptimmune’s stock has been on a wild ride this year, with extreme price swings in recent weeks grabbing headlines. After languishing in penny-stock territory for months, ADAP suddenly caught fire in late September 2025. On September 19, shares opened at a mere $0.08 but skyrocketed 98% by day’s end to $0.16, then jumped another 30% after-hours to ~$0.20 ts2.tech. This stunning one-day move – without any company-specific catalyst – was accompanied by an enormous volume of 705+ million shares traded (versus ~60 million on an average day) ts2.tech. Market observers noted Adaptimmune as one of
16 October 2025
····
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Figure: Hims & Hers markets a broad telehealth platform for men’s and women’s healthts2.tech. Its stock has surged with the boom in telehealth and weight-loss treatments. Women’s Health Expansion Sparks Rally On Oct. 15, Hims & Hers stunned the market by launching a dedicated menopause/perimenopause care program on its “Hers” telehealth platform. The company said the new service would connect women with personalized hormone therapies (estradiol, progesterone, etc.) to ease symptoms like hot flashes and sleep issuests2.tech. This push into a historically underserved sector (roughly 1.3 million U.S. women enter menopause each year) met eager investor demand. As Benzinga and
16 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

Stock Performance & Recent Trends AbbVie’s stock closed at $230.88 on Oct. 10, 2025marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied (+5% in Europe) after Pfizer announced a U.S. drug-pricing dealreuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals (50-day MA ≈ $214; 200-day MA ≈ $197) remain
11 October 2025
·····
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

Company Background AstraZeneca PLC is a leading Anglo-Swedish pharmaceutical giant specializing in oncology, respiratory, cardiovascular/metabolic, and rare disease medicinesmarketbeat.comastrazeneca.com. Headquartered in Cambridge, UK, it maintains primary listings on the London Stock Exchange and Nasdaq Stockholm, with secondary ADR trading in the U.S.astrazeneca.com. The company was formed in 1999 by merging Sweden’s Astra AB and the UK’s Zeneca. Its 2024 revenues were $54.07 billionastrazeneca.com, driven by top-selling drugs like Tagrisso (lung cancer), Lynparza (ovarian cancer), Farxiga (diabetes), and Symbicort (asthma)marketbeat.com. In its 2024 Annual Report, AZN describes itself as “a global, science-led, patient-focused pharmaceutical business” and targets $80B in sales by 2030
11 October 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Metric Merck (MRK) Last Price (10/10/25) $86.02marketbeat.com Market Cap $215Bmarketbeat.com P/E (TTM) ~13×marketbeat.com Yield 3.8%marketbeat.com 52-Week Range $73.31 – $111.58marketbeat.com YTD Total Return -11.07%financecharts.com Q2 2025 Sales $15.8Binvesting.com 2024 Sales $64.2Bmerck.com 2024 R&D Spend $17.9Bmerck.com Analyst PT (avg) $104 (12-mo)marketbeat.com Consensus Rating Holdmarketbeat.com Company Overview Merck & Co. (MRK, called MSD outside North America) is a global healthcare company (75,000 employeesmerck.com) organized in Pharmaceuticals, Vaccines and Animal Health. It focuses on oncology/immunology, infectious disease (including vaccines), cardio-metabolic, and hospital specialty medicinesmerck.com. Its blockbuster product KEYTRUDA® (pembrolizumab) – a PD-1 checkpoint inhibitor – has driven Merck’s growth, accounting for >50% of pharma sales in
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseasesprotagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platformprotagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership & Culture: President
11 October 2025
·······
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Forecast: Experts believe that within the next 2–3 years, we’ll know if Novo’s gamble pays off. Phase 3 readouts for efruxifermin are anticipated in 2026, and Novo hopes to launch the drug by late this decade if approvedreuters.com. By then, the landscape may include other new NASH therapies (possibly Lilly’s or Madrigal’s), but Novo’s combination strategy could set it apart. Wolfe Research analyst Andy Chen recently said the field has reached a “meaningful tipping point” as the first therapies emerge, predicting the leading NASH drug could see $5 billion+ in annual sales under broad useinvesting.com. Novo’s own management clearly shares that optimism – they characterize EFX
9 October 2025
·
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Current News & October 2025 Updates EMA Positive Opinion: A major recent catalyst for Acurx came on September 30, 2025, when the EMA’s Paediatric Committee issued a positive opinion on the Pediatric Investigation Plan (PIP) for Acurx’s lead drug, ibezapolstat, in Clostridioides difficile infectioninvesting.com. This essentially means European regulators agree with Acurx’s plan to study ibezapolstat in children, a prerequisite for future marketing approval in Europe. As the company noted, the PIP approval “ensur[es] necessary data are obtained to support the drug’s authorization and use in pediatric populations.”investing.com This news helped lift ACXP stock from about $4.18 to $4.60 at the end of that weeknasdaq.com, reflecting investor optimism about Acurx’s
8 October 2025
·····
1 … 52 53 54 55 56

Stock Market Today

Compass Group PLC stock price slips to 2,125p as AI worries hang over office catering demand

Compass Group PLC stock price slips to 2,125p as AI worries hang over office catering demand

7 February 2026
London, Feb 7, 2026, 09:22 GMT — Market closed Compass Group PLC (CPG.L) shares closed down 2.48% at 2,125 pence on Friday, lagging a 0.59% rise in the FTSE 100. The stock is trading ex-dividend ahead of a final payout due on Feb. 26 and sits about 26% below its 52-week high. (Hargreaves Lansdown) The move came as the market digested a busy week for the contract caterer, despite a trading update that pointed to steady demand. Investors have instead latched onto a different question: what happens to office footfall if artificial intelligence starts to bite into white-collar jobs. In
Meta stock faces an AI split: ad gains vs a $135 billion bill

Meta stock faces an AI split: ad gains vs a $135 billion bill

7 February 2026
Meta shares dropped 1.3% to $661.46 on Friday after the company projected 2026 capital spending of up to $135 billion, raising investor concerns over cash flow. Meta reported Q4 revenue of $59.89 billion, up 24% year-over-year, with ad impressions rising 18%. Analysts remain divided on whether AI-driven ad gains can offset the steep spending ramp.
IAG share price jumps toward a 52-week peak — what to watch before London reopens

IAG share price jumps toward a 52-week peak — what to watch before London reopens

7 February 2026
IAG shares rose 4.33% to 438.50 pence Friday, near their 52-week high, ahead of full-year results due later this month. The company reported 162,073,135 treasury shares and total voting rights of 4,565,128,012. Brent crude fell 2.2% Thursday to $67.93 a barrel. South Europe Ground Services logged 712,340 operations in 2025 and seeks approval to operate in Portugal.
Binance scoops up 3,600 more Bitcoin for SAFU as BTC whipsaws after brutal selloff

Binance scoops up 3,600 more Bitcoin for SAFU as BTC whipsaws after brutal selloff

7 February 2026
Binance bought 3,600 bitcoin for its Secure Asset Fund, bringing its holdings to 6,230 BTC after bitcoin rebounded above $70,000 following a sharp drop. The broader crypto market lost about $2 trillion since October, with $1 billion in leveraged bitcoin positions liquidated in 24 hours. Strategy reported a wider Q4 loss as bitcoin fell. Gemini will cut up to 200 jobs and exit the UK, EU, and Australia.
Go toTop